NCT02581111View on ClinicalTrials.gov

Naloxone for Optimizing Hypoxemia Of Lung Donors

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 22, 2017

Study Completion Date

September 25, 2017

Conditions
Brain DeathOrgan DonorsLung Transplantation
Interventions
DRUG

Naloxone

Naloxone 8-mg IV bolus

DRUG

Normal saline

Trial Locations (4)

43212

Lifeline of Ohio, Columbus

63110

Mid-America Transplant Services, St Louis

70002

Louisiana Organ Procurement Agency, Metairie

80246

Donor Alliance, Denver

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT02581111 - Naloxone for Optimizing Hypoxemia Of Lung Donors | Biotech Hunter | Biotech Hunter